Last reviewed · How we verify
Quetiapine or Risperidone + Aripiprazole
These atypical antipsychotics block dopamine and serotonin receptors in the brain to reduce psychotic symptoms and stabilize mood.
These atypical antipsychotics block dopamine and serotonin receptors in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar disorder, Major depressive disorder (adjunctive treatment).
At a glance
| Generic name | Quetiapine or Risperidone + Aripiprazole |
|---|---|
| Also known as | Abilify |
| Sponsor | Otsuka Pharmaceutical Development & Commercialization, Inc. |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor, serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Quetiapine and risperidone are second-generation antipsychotics that antagonize dopamine D2 and serotonin 5-HT2A receptors, reducing positive symptoms of psychosis. Aripiprazole is a partial dopamine agonist that modulates rather than fully blocks dopamine signaling. When combined, these agents provide complementary mechanisms for treating psychotic and mood disorders.
Approved indications
- Schizophrenia
- Bipolar disorder
- Major depressive disorder (adjunctive treatment)
- Acute agitation
Common side effects
- Sedation
- Weight gain
- Metabolic syndrome
- Extrapyramidal symptoms
- Orthostatic hypotension
- Prolactin elevation
- QT prolongation
Key clinical trials
- Enhancing Recovery in Early Schizophrenia (PHASE2)
- Magnetic Seizure Therapy for Psychotic Disorders (NA)
- National Pregnancy Registry for Psychiatric Medications
- Maternal And Infant Antipsychotic Study
- Measurement of Treatment Effects (EARLY_PHASE1)
- A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (PHASE3)
- A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal
- Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: